Secondary Infection and Co-infection in COVID-19 Patients Receiving Tocilizumab

Objective: Tocilizumab (TCZ) is a recombinant humanized anti-IL-6 receptor monoclonal antibody that is beneficial in critically ill COVID-19 patients. However, the clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and anakinra) in COVID-19 patients are not yet know...

Full description

Bibliographic Details
Published in:Türk Yoğun Bakim Derneği Dergisi
Main Authors: Çağla Erdoğan, Metin Kılınç, Beyza Şahin, Hülya Sungurtekin
Format: Article
Language:English
Published: Turkish Society of Intensive Care 2024-06-01
Subjects:
seconder infection
covid-19
tocilizumab
Online Access:https://www.turkishjic.org/articles/secondary-infection-and-co-infection-in-covid-19-patients-receiving-tocilizumab/doi/tybd.galenos.2023.59354

Internet

https://www.turkishjic.org/articles/secondary-infection-and-co-infection-in-covid-19-patients-receiving-tocilizumab/doi/tybd.galenos.2023.59354

Similar Items